May 22, 2017Open Access
View Full PaperOral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Key Points
Key points are not available for this paper at this time.
Abstract
Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .).